Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|December 1, 2005
- Pharmaceutical Executive-12-01-2005
- Volume 0
- Issue 0
So You Think You Know Pharma?
PharmExec's 2005 Pharma Knowledge Quiz
Advertisement
Articles in this issue
almost 21 years ago
PharmExec's 2006 Forecastalmost 21 years ago
Thought Leader: A Q&A with Graham Allawayalmost 21 years ago
Marketing to Professionals: Appealing to Doctor's Emotionsalmost 21 years ago
The PharmExec 2005 Pipeline Reportalmost 21 years ago
From the Editor: Double-Standard Drugsalmost 21 years ago
Global Report: Wanted: Attentionalmost 21 years ago
How Much Do You Really Know About Pharma: Quiz Answersalmost 21 years ago
Washington Report: Big Productionalmost 21 years ago
Leadership: Where Have All the Heroes Gone?almost 21 years ago
Inside DDMAC: A Conversation with Thomas AbramsAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5